Cancer treatment-induced oral mucositis

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1105-1125

  Alterio, Daniela ^a   Jereczek Fossa, Barbara Alicja ^a,b   Fiore, Maria Rosaria ^a   Piperno, Gaia ^a   Ansarin, Mohssen ^a   Orecchia, Roberto ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer; Chemotherapy; Mucositis; Radiotherapy; Review

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; AMPHOTERICIN B; AZELASTINE; BENZOCAINE; BENZYDAMINE; CHAMOMILE; CHLORHEXIDINE; COUMARIN; EPIDERMAL GROWTH FACTOR; FLUORIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; ISEGANAN; KAOLIN PECTIN; KERATINOCYTE GROWTH FACTOR; NYSTATIN; PENTOXIFYLLINE; POVIDONE IODINE; PROSTAGLANDIN; RETINOL; SILVER NITRATE; SODIUM CHLORIDE; SUCRALFATE; SUPEROXIDE DISMUTASE; TRICYCLIC ANTIDEPRESSANT AGENT; TROXERUTIN; UNINDEXED DRUG; URIDINE; ZINC SULFATE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL FEATURE; CONSTIPATION; CRYOTHERAPY; HELIUM NEON LASER; HUMAN; MEDLINE; MOUTH HYGIENE; MOUTHWASH; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

HUMANS; RADIATION INJURIES; STOMATITIS;

EID: 34247146542     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (298)

1. Karthaus M, Rosenthal C and Ganser: A Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis - are there new strategies? Bone Marrow Transplant 24(10): 1095-1108, 1999.
2. Bensadoun RJ, Magne N, Marcy PY and Demard F: Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol 258(9): 481-487, 2001.
3. Scully C, Epstein J and Sonis S: Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 1: pathogenesis and prophylaxis of mucositis. Head Neck 25(12): 1057-1070, 2003.
4. Scully C, Epstein J and Sonis S: Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck 26(1): 77-84, 2004.
5. Kostler WJ, Hejna M, Wenzel C and Zielinski CC: Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment CA. Cancer J Clin 51(5): 290-315, 2001.
6. Toth BB, Chambers MS, Fleming TJ, Lemon JC and Martin JW: Minimizing oral complications of cancer treatment. Oncology (Huntingt) 9(9): 851-858; discussion, 858: 863-866, 1995.
7. Raber-Durlacher JE: Current practices for management of oral mucositis in cancer patients. Support Care Cancer 7(2): 71-74, 1999.
8. Shih A, Miaskowski C, Dodd MJ, Stotts NA and Macphail L: A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncol Nurs Forum 29(7): 1063-1080, 2002.
9. Symonds RP: Treatment-induced mucositis: an old problem with new remedies. Br J Cancer 77(10): 1689-1695, 1998.
10. Rugg T, Saunders MI and Dische S: Smoking and mucosal reactions to rad iotherapy. Br J Radiol 63(751): 554-556, 1990.
11. Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP and Hayat M: Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 30B(2): 93-97, 1994.
12. Shieh SH, Wang ST, Tsai ST and Tseng CC: Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncol 33(1): 36-41, 1997.
13. Jansma J, Vissink A, Spijkervet FK, Roodenburg JL, Panders AK, Vermey A, Szabo BG and Gravenmade EJ: Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 70(8): 2171-2180, 1992.
14. Janjan NA, Weissman DE and Pahule A: Improved pain management with daily nursing intervention during radiation therapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 23(3): 647-652, 1992.
15. Djuric M, Hillier-Kolarov V, Belic A and Jankovic L: Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer 14(2): 137-146, 2006.
16. Feber T: Mouth care for patients receiving oral irradiation. Prof Nurse 10(10): 666-670, 1995.
17. Maire F, Borowski B, Collangettes D, Farsi F, Guichard M, Gourmet R and Kreher P: standards, options and recommendations (SOR) for good practices in dentistry for head and neck cancer patients. Federation of the French Cancer Centres (FNCLCC) Bull Cancer 86(7-8): 640-665, 1999.
18. Dodd MJ, Miaskowski C, Shiba GH, Dibble SL, Greenspan D, MacPhail L, Paul SM and Larson P: Risk factors for chemotherapy-induced oral mucositis: dental appliances. Oral Cancer Invest 17(4): 278-284, 1999.
19. Ezzone S, Jolly D, Replogle K, Kapoor N and Tutschka PJ: Survey of oral hygiene regimens among bone marrow transplant centers. Oncol Nurs Forum 20(9): 1375-1381, 1993.
20. Dodd MJ, Dibble SL, Miaskowski C, MacPhail L, Greenspan D, Paul SM, Shiba G and Larson P: Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90(1): 39-47, 2000.
21. Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, MacPhail L, Hauck WW, Paul SM, Ignoffo R and Shiba G: Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 23(6): 921-927, 1996.
22. Matsuoka H, Mizushima Y, Kawano M, Tachibana N, Sawada Y, Kato S, Nagakura H, Tanaka M, Suzuki K and Tadanobu K: Clinical availability of the herbal medicine, SYOUSAIKOTOU, as a gargling agent for prevention and treatment of chemotherapy-induced stomatitis. Gan To Kagaku Ryoho 31(12): 2017-2020, 2004.
23. Mazokopakis EE, Vrentzos GE, Papadakis JA, Babalis DE and Ganotakis ES: Wild chamomile (Matricaria recutita L.) mouthwashes in methotrexate-induced oral mucositis. Phytomedicine 12(1-2): 25-27, 2005.
24. Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL, Novotny P, Clemens-Schutjer D, Bartel J and Michalak JC: Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 77(3): 522-525, 1996.
25. Sonis ST, Clairmont F, Lockhart PB and Connolly SF: Benzydamine HCL in the management of chemotherapy-induced mucositis. I. Pilot study. J Oral Med 40(2): 67-71, 1985.
26. Cheng KK, Chang AM and Yuen MP: Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 40(8): 1208-1216, 2004.
27. Pfeiffer P, Madsen EL, Hansen O and May O: Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol 29(2): 171-173, 1990.
28. Allison RR, Vongtama V, Vaughan J and Shin KH: Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Invest 13(1): 16-22, 1995.
29. Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, Siu LL, pond G and Moore MJ: Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Support Care Cancer 11(1): 41-47, 2003.
30. Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR and Tornton D: Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 113(4): 758-763, 1988.
31. Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC, Schaefer PL, Novotny PG, Gerstner JB, White DF, Hatfield AK and Ouella SK: Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol 15(3): 1235-1238, 1997.
32. Chiara S, Nobile MT, Vincenti M, Gozza A, Pastrone I, Rosso M and Rosso R: Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study. Anticancer Res 21(5): 3707-3710, 2001.
33. Porteder H, Rausch E, Kment G, Watzek G, Matejka M and Sinzinger H: Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg 16(8): 371-374, 1988.
34. Verdi CJ, Garewal HS, Koenig LM, Vaughn B and Burkead T: A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80(1): 36-42, 1995.
35. Ciais G, Namer M, Schneider M, Demard F, Pourreau-Scheneider N, Martin PM, Soudry M, Franquin JC and Zattara H: Laser therapy in the prevention and treatment of mucositis caused by anticancer chemotherapy. Bull Cancer 79(2): 183-1891, 1992.
36. Nes AG and Posso MB: Patients with moderate chemotherapy-induced mucositis: pain therapy using low intensity laser. International Council of Nurses. Int Nurs Rev 52(1): 68-72, 2005.
37. Wong SF and Wilder-Smith P: Pilot study of laser effects on oral mucositis in patients receiving chemotherapy. Cancer J 8(3): 247-254, 2002.
38. Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, Sorensen JM, Gainey DH, Maillard JA, Gusa NL et al: Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9(3): 449-452, 1991.
39. Cascinu S, Fedeli A, Fedeli SL and Catalano G: Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil- induced stomatitis. Eur J Cancer B Oral Oncol 30B(4): 234-236, 1994.
40. Nikoletti S, Hyde S, Shaw T, Myers H and Kristjanson LJ: Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs 14(6): 750-753, 2005.
41. Karagozoglu S and Filiz Ulusoy M: Chemotherapy: the effect of oral cryotherapy o the development of mucositis. J Clin Nurs 14(6): 754-765, 2005.
42. Gandara DR, Edelman MJ, Crowley JJ, Lau DH and Livingston RB: Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol 41(1): 75-81, 1997.
43. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrel C, Uhric M and Meyer F: Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs 16(1): 69-75, 1998.
44. Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D and Coiffier B: Prevention of high dose L-PAM- induced mucositis by cryotherapy. Bone Marrow Transplant 14(3): 492-494, 1994.
45. Baydar M, Dikilitas M, Sevine A, Senel S, Senel F and Aydogdu I: Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc 97(8): 1161-1164, 2005.
46. Tartarone A, Matera R, Romano G, Vigliotti ML and Di Renzo N: Prevention of high-dose melphalan-induced mucositis by cryotherapy. Leuk Lymphoma 46(4): 633-634, 2005.
47. Chi KH, Chen CH, Chan WK, Chow KC, Chen SY, Yen SH, Chao JY, Chang CY and Chen KY: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 13(10): 2620-2628, 1995.
48. Hejna M, Kostler WJ, Raderer M, Steger GG, Brodowicz T, Scheithauer W, Wiltschke C and Zielinski CC: Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer 37(16): 1994-2002, 2001.
49. Rossi A, Rosati G, Colarusso D and Manzione L: Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. Oncology 64(4): 353-360, 2003.
50. Ibrahim EM and Al-Mulhim FA: Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Med Oncol 14(1): 47-51, 1997.
51. Moore DF Jr and Pazdur R: Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor. Am J Clin Oncol 15(6): 464-466, 1992.
52. Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C and Maccio A: Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Rep 10(1): 197-206, 2003.
53. Katano M, Nakamura M, Matsuo T, Iyama A and Hisatsugu T: Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. Surg Today 25(3): 202-206, 1995.
54. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318(22): 1414-1422, 1988.
55. Crawford J, Tomita DK, Mazanet R, Glaspy J and Ozer H: Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 5(4): 187-193, 1999.
56. Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, Sluiter WJ, van Buuren AH, Mulder NH and de Vries EG: Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res 5(6): 1363-1368, 1999.
57. Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG, Reed E, Sonis ST, Fay J, LeVeque F, Pouillart P, Schrezenmeier H, Emmons R and Thiel E: Investigation in TGF-beta3/OM Study Protocols 203/205. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother 24(4): 384-388, 2001.
58. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, Rothenberg ML, Redding SW, Serdar CM, Yao B, Heard R and Rosen LS: Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 21(8): 1452-1458, 2003.
59. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, Brunvand MM and Martin PJ: A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma 44(7): 1165-1172, 2003.
60. Dodd MJ, Miaskowski C, Greenspan D, MacPhail L, Shih AS, Shiba G, Facione N and Paul SM: Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes. Cancer Invest 21(1): 21-33, 2003.
61. Pitten FA, Kiefer T, Buth C, Doelken G and Kramer A: Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. J Hosp Infect 53(4): 283-291, 2003.
62. Wahlin YB: Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 68(3): 279-287, 1989.
63. Luglie PF, Mura G, Mura A, Angius A, Soru G and Farris A: Prevention of periodontopathy and oral mucositis during antineoplastic chemotherapy. Clinical study Minerva Stomatol 51(6): 231-239, 2002.
64. Cheng KK, Molassiotis A, Chang AM, Wai WC and Cheung SS: Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer 37(16): 2056-2063, 2001.
65. Cheng KK and Chang AM: Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nurs 26(6): 476-484, 2003.
66. Barrett AP: Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients. Oral Surg Oral Med Oral Pathol 58(2): 148-151, 1984.
67. Lefebvre JL and Domenge C; Study Group of Mucositis: A comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositis. Oral Oncol 38(4): 337-342, 2002.
68. Brincker H: Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Med Scand 204(1-2): 123-128, 1978.
69. Jordan WM, Bodey GP, Rodriguez V, Ketchel SJ and Henney J: Miconazole therapy for treatment of fungal infections in cancer patients. Antimicrob Agents Chemother 16(6): 792-797, 1979.
70. Yeo E, Alvarado T, Fainstein V and Bodey GP: Prophylaxis of oropharyngeal candidiasis with clotrimazole. J Clin Oncol 3(12): 1668-1671, 1985.
71. Shechtman LB, Funaro L, Robin T, Bottone EJ and Luttner J: Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med 76(1): 91-94, 1984.
72. Epstein JB, Gorsky M and Caldwell J: Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93(6): 671-675, 2002.
73. Finlay PM, Richardson MD and Robertson AG: A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Br J Oral Maxillofac Surg 34(1): 23-25, 1996.
74. Kubesova H, Penka M, Kral Z, Adam Z, Vasova I, Tomiska M and Vorlicek J: Herpes simplex infection as possible etiology for febrile neutropenia and mucositis in patients treated for hematological malignancies. Acta Med Austriaca 25(2): 57-60, 1998.
75. Cockerham MB, Weinberger BB and Lerchie SB: Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 34(3): 300-303, 2000.
76. Skubitz KM and Anderson PM: Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med 127(2): 223-228, 1996.
77. Anderson PM, Ramsay NK, Shu XO, Rydholm N, Rogosheske J, Nicklow R, Weisdorf DJ and Skubitz KM: Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 22(4): 339-344, 1998.
78. Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M and Schlag PM: Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 35(2): 202-207, 1999.
79. Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D, Shelley MD and Elia M: 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 70(4): 732-735, 1994.
80. van Zaanen HC, van der Lelie H, Timmer JG, Furst P and Sauerwein HP: Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 74(10): 2879-2884, 1994.
81. Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D, Swan D, Axvig C, Ebbert LP, Tirona MR, Michalak JC and Pierson N: Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol 22(3): 258-261, 1999.
82. Carnel SB, Blakeslee DB, Oswald SG and Barnes M: Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 102(4): 326-330, 1990.
83. Turhal NS, Erdal S and Karacay S: Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer 8(1): 55-58, 2000.
84. LeVeque FG, Parzuchowski JB, Farinacci GC, Redding SW, Rodu B, Johnson JT, Ferretti GA, Eisenberg PD and Zimmer MB: Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy. J Clin Oncol 10(12): 1963-1968, 1992.
85. Redding SW: Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 9: 103-105, 1990.
86. Yamamura K, Ohta S, Yano K, Yotsuyanagi T, Okamura T and Nabeshima T: Oral mucosal adhesive film containing local anesthetics: in vitro and clinical evaluation. J Biomed Mater Res 43(3): 313-317, 1998.
87. Epstein JB, Truelove EL, Oien H, Allison C, Le ND and Epstein MS: Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. Oral Oncol 37(8): 632-637, 2001.
88. De Souza CA, Santini G, Marino G, Nati S, Congiu AM, Vigorito AC and Damasio E: Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. Braz J Med Biol Res 33(7): 791-798, 2000.
89. Fahlke J, Ridwelski K and Lippert H: High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. Int J Colorectal Dis 14(2): 128-130, 1999.
90. Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG and Roodenburg JL: Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer 88(7): 1012-106, 2003.
91. Wadleigh RG, Redman RS, Graham ML, Krasnow SH, Anderson A and Cohen MH: Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 92(5): 481-484, 1992.
92. Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G and Dreyfus F: Treatment of mucositis with vitamin E during administration of neutropenic antineoplastic agents. Ann Med Interne (Paris) 145(6): 405-408, 1994.
93. Thornley I, Lehmann LE, Sung L, Holmes C, Spear JM, Brennan L, Vangel M, Bechard LJ, Richardson P, Duggan C and Guinan EC: A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 10(9): 635-644, 2004.
94. Clark PI and Slevin ML: Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. Eur J Surg Oncol 11(3): 267-268, 1985.
95. Tsavaris NB, Komitsopoulou P, Tzannou I, Loucatou P, Tsaroucha-Noutsou A, Kilafis G and Kosmidis P: Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil. Sel Cancer Ther 7(3): 113-117, 1991.
96. Howell SB, Pfeifle CE and Wung WE: Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 51(2): 220-225, 1983.
97. Porta C, Moroni M and Nastasi G: Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 17(3): 246-247, 1994.
98. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL and Alberts DS: A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol 37(3): 354-358, 1990.
99. Loprinzi CL, Cianflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM, Hagen L, Gainey DK, Cross M, Athmann LM et al: A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 65(8): 1879-1882, 1990.
100. Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al Qady A, Jamhoury A, Daniel M, Charles C, Ambrose A and El-Aloosy AS: Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. Eur J Cancer 37(16): 2010-2014, 2001.
101. Berger A, Henderson M, Nadoolman W, Duffy V, Cooper D, Saberski L and Bartoshuk L: Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy. J Pain Symptom Manage 10(3): 243-248, 1995.
102. Yuki F, Kawaguchi T, Hazemoto K and Asou N: Preventive effects of oren-gedoku-to on mucositis caused by anticancer agents in patients with acute leukaemia. Gan To Kagaku Ryoho 30(9): 1303-1307, 2003.
103. Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J and Sawyer R: Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. Cancer 71(5): 1875-1881, 1993.
104. Malik IA, Moid I, Haq S and Sabih M: A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis. J Pain Symptom Manage 14(2): 82-87, 1997.
105. Coetxee MJ, Boshoff B, Goedhals L and Pienaar FD: Formula C-popular, cheep and readily available relief for radiation and cancer chemotherapy mucositis. S Arf Med J 87(1): 80-81, 1997.
106. Feber T: Management of mucositis in oral irradiation. Clin Oncol 8(2): 106-111, 1996.
107. Janjan NA, Weissman DE and Pahule A: Improved pain management with daily nursing intervention during radiation therpy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 23(3): 647-652, 1992
108. Carl W and Emrich LS: Management of oral mucositis during local radiation and systemic chemotherapy: a study of 98 patients. J Prosthet Dent 66(3): 361-369, 1991.
109. Biswal BM, Zakaria A and Ahmad NM: Topical application of honey in the management of radiation mucositis: a preliminary study. Support Care Cancer 11(4): 242-248, 2003.
110. Rothwell BR and Spektor WS: Palliation of radiation-related mucositis. Spec Care Dentist 10(1): 21-25, 1990.
111. Kim JH, Chu FC, Lakshmi V and Houde R: Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 9(2): 132-134, 1986.
112. Schubert MM and Newton RE: The use of benzydamine HCl for the management of cancer therapy-induced mucositis: preliminary report of a multicentre study. Int J Tissue React 9(2): 99-103, 1987.
113. Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS and Ferguson MM: The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clin Radiol 39(3): 291-294, 1988.
114. Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, Senzer NN, Lockhart PB, Gallagher MJ, Peterson DE and Leveque FG: Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92(4): 875-885, 2001.
115. Scherlacher A and Beaufort-Spontin F: Radiotherapy of headneck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment. HNO 38(1): 24-28, 1990.
116. Franzen L, Henriksson R, Littbrand B and Zackrisson B: Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study. Acta Oncol 34(2): 219-223, 1995.
117. Cengiz M, Ozyar E, Ozturk D, Akyol F, Atahan IL and Hayran M: Sucralfate in the prevention of radiation-induced oral mucositis. J Clin Gastroenterol 28(1): 40-43, 1999.
118. Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH, Tulunay O and Cakmak A: Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol 36(1): 116-1120, 2000.
119. Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J and Joensuu H: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys 46(3): 525-534, 2000.
120. Epstein JB and Wong FL: The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 28(3): 693-698, 1994.
121. Makkonen TA, Bostrom P, Vilja P and Joensuu H: Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 30(1): 177-182, 1994.
122. Carter DL, Hebert ME, Smink K, Leopold KA, Clough RL and Brizel DM: Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. Head Neck 21(8): 760-766, 1999.
123. Lievens Y, Haustermans K, Van den Weyngaert D, Van den Bogaert W, Scalliet P, Hutsebaut L, Fowler J and Lambin P: Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 47(2): 149-153, 1998.
124. Saarilahti K, Kajanti M, Joensuu T, Kouri M and Joensuu H: Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation- induced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys 54(2): 479-485, 2002.
125. Evensen JF, Bjordal K, Jacobsen AB, Lokkevike E and Tansjo JE: Effects of Na-sucrose octasulfate on skin and mucosa reactions during radiotherapy of head and neck cancers. Acta Oncol 40(6): 751-755, 2001.
126. Meredith R, Salter M, Kim R, Spencer S, Weppelmann B, Rodu B, Smith J and Lee J: Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 37(2): 275-279, 1997.
127. Belka C, Hoffmann W, Paulsed F and Barnberg M: The use of sucralfate in radiation oncology. Strahlenther Onkol 173(5): 247-252, 1997
128. Barker G, Loftus L, Cuddy P and Barker B: The effects of sucralfate suspension and diphenhydramine syrup plus kaolinpectin on radiotherapy-induced mucositis Oral Surg Oral Med Oral Pathol 71(3): 288-293, 1991.
129. Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE and Tova Y: Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: A placebo-controlled, double-blind clinical trial. Am J Ther 2(11): 850-857, 1995.
130. Maciejewski B, Zajusz A, Pilecki B, Swiatnicka J, Skladowski K, Dorr W, Kummermehr J and Trott KR: Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer. Radiother Oncol 22(1): 7-11, 1991.
131. Dorr W, Jacubek A, Kummermehr J, Herrmann T, Dolling-Jochem I and Eckelt U: Effects of stimulated repopulation on oral mucositis during conventional radiotherapy. Radiother Oncol 37(2): 100-107, 1995.
132. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M, Dejou J, Tardieu C, Benezery K, Nguyen TD, Laudoyer Y, Dassonville O, Poissonnet G, Vallicioni J, Thyss A, Hamdi M, Chauvel P and Demard F: Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 7(4): 244-252, 1999.
133. Perch SJ, Machtay M, Markiewicz DA and Kligerman: Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx. Radiology 197(3): 863-866, 1995.
134. Troussard X, Macro M, Vie B, Batho A, Peny AM, Reman O, Tabah I and Leporrier M: Human recombinant granulocyte-macrophage colony stimulating factor (hrGM-CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: a pilot study. Br J Haematol 89(1): 191-195, 1995.
135. Kannan V, Bapsy PP, Anantha N, Doval DC, Vaithianathan H, Banumathy G, Reddy KB, Kumaraswamy SV and Shenoy MK: Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys 37(5): 1005-1010, 1997.
136. Nicolatou-Galitis O, Dardoufas K, Markoulatos P, Sotiropoulou-Lontou A, Kyprianou K, Kolitsi G, Pissakas G, Skarleas C, Kouloulias V, Papanicolaou V, Legakis NJ and Velegraki A: Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. J Oral Pathol Med 30(8): 471-480, 2001.
137. Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, Kyprianou K, Kolitsi G and Dardoufas K: A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Int J Radiat Oncol Biol Phys 42(3): 551-556, 1998.
138. Rovirosa A, Ferre J and Biete A: Granulocyte macrophage-colony- stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys 41(4): 747-754, 1998.
139. de la Torre A, Reguiero CA and Valcarcel FJ: Granulocyte-macrophage colony-stimulating factor mouthwashes improve radiation induced mucositis in AIDS patients. Radiother Oncol 43(2): 229-230, 1997.
140. Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, Alenius M and Lewensohn R: Therapeutic efficacy by recombinant human granulocyte/moncyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Med Oncol 22(3): 247-256, 2005.
141. Mascarin M, Franchin G, Minatel E, Gobitti C, Talamini R, De Maria D and Trovo MG: The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol 35(2): 203-208, 1999.
142. Wagner W, Alfrink M, Haus U and Matt J: Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Anticancer Res 19(1B): 799-803, 1999.
143. Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M, Contreras R and Juillard GF: Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: an interim look at a randomized, double-blind, placebo-controlled trial. Cytokines Cell Mol Ther 5(3): 175-180, 1999.
144. Symonds RP, McIlroy P, Khorrami J, Paul J, Pyper E, Alcock SR, McCallum I, Speekenbrink AB, McMurray A, Lindemann E and Thomas M: The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 74(2): 312-317, 1996.
145. Matthwes RH and Ercal N: Prevention of mucositis in irradiated head and neck cancer patients. J Exp Ther Oncol 1(2): 135-138, 1996.
146. Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, Uges DR and Hospers GA: Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Res 24(5B): 3263-3267, 2004.
147. Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD, Wilims EB, van der Est H and Visch LL: Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 50(2): 343-352, 2001.
148. El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M, MacKenzie R, Read N, Berthelet E, Lau H, Epstein J, Delvecchio P, Ganguly PK, Wong F, Burns P, Tu D and Pater J: Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 20(19): 3956-3963, 2002.
149. Spijkervet FK, Van Saene HK, Van Saene JJ, Panders AK, Vermey A, Mehta DM and Fidler V: Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 46(3): 167-173, 1991.
150. El-Sayed S, Epstein J, Minish E, Burns P, Hay J and Laukkanen E: A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck 24(1): 6-15, 2002.
151. Oguchi M, Shikama N, Sasaki S, Gomi K, Katsuyama Y, Ohta S, Hori M, Takei K, Arakawa K and Sone S: Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis. Int J Radiat Oncol Biol Phys 40(5): 1033-1037, 1998.
152. Ferretti GA, Raybould TP, Brown AT, Macdonald JS, Greenwood M, Maruyama Y, Geil J, Lillich TT and Ash RC: Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol 69(3): 331-338, 1990.
153. Spijkervet FK, van Saene HK, van Saene JJ, Panders AK, Vermey A and Mehta DM: Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients. J Oral Pathol Med 19(10): 486-489, 1990.
154. Spijkervet FK, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM and Fidler V: Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol 67(2): 154-1561, 1989.
155. Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH, Ryan MA, Earle JM and Novotny P: Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 12(12): 2630-2633, 1994.
156. Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, Rosenthal DI, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B and Ang KK: A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58(3): 674-681, 2004.
157. Yap BS and Bodey GP: Oropharyngeal candidiasis treated with a troche form of clotrimazole. Arch Intern Med 139(6): 656-657, 1979.
158. Mucke R, Kaben U, Libera T, Knauerhase H, Ziegler PG, Hamann D and Strietzel M: Use of fluconazole as antimycotic prophylaxis in radiotherapy of patients with head and neck tumors. Mycoses 40 Suppl 1: 53-55, 1997.
159. Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E and Antoniades D: Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 19(6): 347-351, 2004.
160. Bubley GJ, Chapman B, Chapman SK, Crumpacker CS and Schnipper LE: Effect of acyclovir on radiation- and chemotherapy-induced mouth lesion. Antimicrob Agents Chemother 33(6): 862-865, 1989.
161. Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, Yeh SA, Hsu HC and Hsiung CY: Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 46(3): 535-539, 2000.
162. Shaiova L, Lapin J, Manco LS, Shasha D, Hu K, Harrison L and Portenoy RK: Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support Care Cancer 12(4): 268-273, 2004.
163. Carnel SB, Blakeslee DB, Oswald SG and Barnes M: Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 102(4): 326-330, 1990.
164. Alterio D, Jereczek-Fossa BA, Zuccotti GF, Leon ME, Omodeo Sale E, Pasetti M, Modena T, Perugini P, Mariani L and Orecchia R: Tetracaine oral gel in patients treated with radiotherapy for head and neck cancer: final results of a phase II study. Int J Radiat Oncol Biol Phys 64(2): 392-395, 2006.
165. Slatkin NE and Rhiner M: Topical ketamine in the treatment of mucositis pain. Pain Med 4(3): 298-303, 2003.
166. Ehrnrooth E, Grau C, Zachariae R and Andersen J: Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncol 40(6): 745-750, 2001.
167. Antonadou D, Pepelassi M, Synodinou M, Puglisi M and Throuvalas N: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52(3): 739-747, 2002.
168. Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, Luboinski B, Wibault P and Eschwege F: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46(5): 1105-1108, 2000.
169. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W and Sauer R: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18(19): 3339-3345, 2000.
170. Wagner W, Prott FJ and Schonekas KG: Amifostine: a radioprotector in locally advanced head and neck tumors. Oncol Rep 5(5): 1255-1257, 1998.
171. Schonekas KG, Wagner W and Prott FJ: Amifostine-a radioprotector in locally advanced head and neck tumor. Strahlenther Onkol 175 Suppl 4: 27-29, 1999.
172. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G and Georgoulias V: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 18(11): 2226-2233, 2000.
173. Kouvaris J, Kouloulias V, Kokakis J, Matsopoulos G, Balafouta M, Miliadou A and Vlahos L: Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis. Onkologie 25(4): 364-369, 2002.
174. Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A and Ilha L: Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 26(4): 313-321, 2004.
175. Valdez IH, Wolff A, Atkinson JC, Macynski AA and Fox PC: Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 71(5): 1848-1851, 1993.
176. Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J, Payne D, Bayley A, Ringash J, Kim J, Liu FF, Maxymiw W, Sprague S and Cummings BJ: A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 54(1): 9-13, 2002.
177. Fisher J, Scott C, Scarantino CW, Leveque FG, White RL, Rotman M, Hodson DI, Meredith RF, Foote R, Bachman DG and Lee N: Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer-RTOG 97-09. Int J Radiat Oncol Biol Phys 56(3): 832-836, 2003.
178. Mose S, Adamietz IA, Saran F, Thilmann C, Heyd R, Knecht R and Bottcher HD: Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis? Am J Clin Oncol 20(4): 407-411, 1997.
179. Mose S, Adamietz IA, Thilmann C, Saran F, Heyd R, Knecht R and Bottcher HD: Immunoglobulin for prevention of radiogenic mucositis. HNO 43(7): 421-426, 1995.
180. Leborgne JH, Leborgne F, Zubizarreta E, Ortega B and Mezzera J: Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol 47(2): 145-148, 1998.
181. Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneickevon Zepelin HH, Bockisch A, Kutzner J, Naser-Hijazi B, Belz GG and Wagner W: Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer-a prospective,randomized, placebo-controlled, double-blind study. Br J Oral Maxillofac Surg 39(1): 34-39, 2001.
182. Gujral MS, Patnaik PM, Kaul R, Parikh HK, Conradt C, Tamhankar CP and Daftary GV: Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 47 Suppl: S23-28, 2001.
183. Valencia J, Velilla C, Urpegui A, Alvarez I, Llorens MA, Coronel P, Polo S, Bascon N and Esco R: The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori 88(5): 385-389, 2002.
184. Ertekin MV, Koc M, Karslioglu I and Sezen O: Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys 58(1): 167-174, 2004.
185. Kaushal V, Verma K, Manocha S, Hooda HS and Das BP: Clinical evaluation of human placental extract (placentrex) in radiation-induced oral mucositis. Int J Tissue React 23(3): 105-110, 2001.
186. Oshitani T, Okada K, Kushima T, Suematsu T, Obayashi K, Hirata Y, Takada Y, Ishida T, Yoshida M, Narabayashi I et al: Clinical evaluation of sodium alginate on oral mucositis associated with radiotherapy. Nippon Gan Chiryo Gakkai Shi 25(6): 1129-1137, 1990.
187. Pillsbury HC III, Webster WP and Rosenman J: Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch Otolaryngol Head Neck Surg 112(5): 552-553, 1986.
188. Su CK, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J, Koong A, Goffinet D and Le OT: Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. Int J Radiat Oncol Biol Phys 60(1): 171-177, 2004.
189. Epstein JB, Vickars L, Spinelli J and Reece D: Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 73(6): 682-689, 1992.
190. Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M, Laborda R, Clopes A and Sierra J: Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rh-GM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplant 29(9): 783-787, 2002.
191. Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, Bockova J and Misaniova L: The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high dose chemotherapy and APBSCT - results of a randomized multicentric study. Support Care Cancer 13(7): 554-558, 2005.
192. Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M, Tienghi A, Turci D, Rosti G, Nanni O, Rondoni C and Marangolo M: Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol 14(4): 559-563, 2003.
193. van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML, Timmer JG and von dem Borne AE: Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 80(3): 150-154, 2001.
194. Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E and Miller KB: A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 31(8): 705-712, 2003.
195. Castagna L, Benhamou E, Pedraza E, Luboinski M, Forni M, Brandes I, Pico JL and Dietrich PY: Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. Ann Oncol 12(7): 953-955, 2001.
196. Pretnar J, Glazar D, Mlakar U and Modic M: Prostaglandin E2 in the treatment of oral mucositis due to radiochemotherapy in patients with haematological malignancies. Bone Marrow Transplant 4 Suppl 3: 106, 1989.
197. Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Radman I, Filipovic-Grcic N, Sertic D, Kalenic S et al: Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11(5): 379-382, 1993.
198. Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, Gallardo-Rincon D, Lara-Medina F, Aguilar-Ponce L, Miranda-Lopez E, Zinser-Sierra J and Reynoso-Gomez E: Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 17(5): 809-812, 1996.
199. Ferra C, de Sanjose S, Lastra CF, Marti F, Marino EL, Sureda A, Brunet S, Gallardo D, Berlanga JJ, Garcia J and Granena A: Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 20(12): 1075-1080, 1997.
200. van der Jagt RH, Pari G, McDiarmid SA, Boisvert DM and Huebsch LB: Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 13(2): 203-207, 1994.
201. Lopez J, Cancelas JA, Valino JM, Garcia-Larana J, Sastre JL, Perez-Oteyza J, Cervero C, Garcia-Avello A, Cabezudo E and Arranz MI: Pentoxifylline is not useful in the prevention of toxicity associated with bone marrow transplantation. Med Clin (Barc) 102(13): 485-488, 1994.
202. Stockschlader M, Kalhs P, Peters S, Zeller W, Kruger W, Kabisch H, Lechner K and Zander A: Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 12(4): 357-362, 1993.
203. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, Laurent G and Pris J: Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 82(3): 732-736, 1993.
204. Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, Bensinger WI, Bowden RA, McDonald GB, Schubert M et al: A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 82(7): 2025-2030, 1993.
205. Barasch A, Peterson DE, Tanzer JM, D'Ambrosio JA, Nuki K, Schubert MM, Franquin JC, Clive J and Tutschka P: Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 76(12): 2550-2556, 1995.
206. Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C and Franquin JC: Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 38(4): 697-703, 1997.
207. Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R and Coccia P: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 12(9): 1917-1922, 1994.
208. Ho AD, Del Valle F, Engelhard M, Hiddemann W, Ruckle H, Schlimok G, Haas R, Thiel E, Andreesen R, Fiedler W et al: Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study. Cancer 66(3): 423-430, 1990.
209. Bez C, Demarosi F, Sardella A, Lodi G, Bertolli VG, Annaloro C, Rimondini L, Porter SR and Carrassi A: GM-CSF mouth rinses in the treatment of severe oral mucositis: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88(3): 311-315, 1999.
210. Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML, Hoke JA, Hussein AM, Ross M, Rubin P et al: Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 7(5): 471-477, 1995.
211. Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M, Tienghi A, Turci D, Rosti G, Nanni O, Rondoni C and Marangolo M: Prophylaxys with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high.dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol 14(4): 559-563, 2003.
212. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, Singer JW, Flomenberg N, Dalton W, Elfenbein GJ et al: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 15(6): 949-954, 1995.
213. Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M, Laborda R, Clopes A and Sierra J: Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplant 29(9): 783-787, 2002.
214. van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML, Timmer JG and von dem Borne AE: Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 80(3): 150-154, 2001.
215. Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B, Krauter J, Scharmann T, Geissler RG, Heil G and Ganser A: Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 22(8): 781-785, 1998.
216. Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S and Ferrara JL: A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 29(5): 373-377, 2002.
217. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG and Emmanouilides C: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25): 2590-2598, 2004.
218. Siddiqui MA and Wellington K: Palifermin: in myelotoxic therapy-induced oral mucositis. Drugs 65(15): 2139-2146, 2005.
219. Freytes CO, Ratanatharathorn V, Taylor C, Abboud C, Chesser N, Restrepo A, Arango J and Odenheimer D: Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res 10(24): 8318-8324, 2004.
220. McGaw WT and Belch A: Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen. Oral Surg Oral Med Oral Pathol 60(3): 275-280, 1985.
221. Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH and Lillich TT: Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 3(5): 483-493, 1988.
222. Ferretti GA, Hansen IA, Whittenburg K, Brown AT, Lillich TT and Ash RC: Therapeutic use of chlorhexidine in bone marrow transplant patients: case studies. Oral Surg Oral Med Oral Pathol 63(6): 683-687, 1987.
223. Rutkauskas JS and Davis JW: Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report. Oral Surg Oral Med Oral Pathol 76(4): 441-448, 1993.
224. Epstein JB, Vickars L, Spinelli J and Reece D: Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 73(6): 682-689, 1992.
225. Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B, Ferrieri P, Haake R, Goldman A, Woods W et al: Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 4(1): 89-95, 1989.
226. Raether D, Walker PO, Bostrum B and Weisdorf D: Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatr Dent 11(1): 37-42, 1989.
227. Gava A, Ferrarese F, Tonetto V, Coghetto F, Marazzato G and Zorat PL: Can the prophylactic treatment of mycotic mucositis improve the time of performing radiotherapy in head and neck tumors? Radiol Med (Torino) 91(4): 452-455, 1996.
228. Koc M and Aktas E: Prophylactic treatment of mycotic mucositis in radiotherapy of patients with head and neck cancers. Jpn J Clin Oncol 33(2): 57-60, 2003.
229. Espstein JB, Ransier A, Sherlock CH, Spinelli JJ and Reece D: Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Eur J Cancer B Oral Oncol 32B(3): 158-162, 1996.
230. Eisen D, Essell J, Broun ER, Sigmund D and DeVoe M: Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 31(1): 51-55, 2003.
231. Anderson PM, Schroeder G and Skubitz KM: Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83(7): 1433-1439, 1998.
232. Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Ademas RH, Jackson GB and Sandler ES: A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell tranplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 36(7): 611-616, 2005.
233. Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M, Rutella S, Cicconi S, Fiorini A, D'Onofrio G, Leone G and Sica S: Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 88(2): 192-200, 2003.
234. Schloerb PR and Skikne BS: Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. J Parenter Enteral Nutr 23(3): 117-122, 1999.
235. Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B and Kozak T: Standardized parenteral alanylglutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplant 30(12): 953-961, 2002.
236. Coghlin Dickson TM, Wong RM, offrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG and Stockerl-Goldstein KE: Effect of oral glutamine supplementation during bone marrow transplantation. J Parenter Enteral Nutr 24(2): 61-66, 2000.
237. Coda BA, O'Sullivan B, Donaldson G, Bohl S, Chapman CR and Shen DD: Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 72(3): 333-346, 1997.
238. Demarosi F, Lodi G, Soligo D, Sardella A, Volpe AD, Carrassi A and Deliliers GL: Transdermal fentanyl in HSCT patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone Marrow Transplant 33(12): 1247-1251, 2004.
239. Strupp C, Sudhoff T, Germing U, Hunerliturkoglu A, Schneider P, Niederste-Hollenberg A, Heyll A and Aul C: Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol Rep 7(3): 659-661, 2000.
240. Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC and Frenette G: Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplantation 35(7): 713-720, 2005.
241. Cohen G, Elad S, Or R, Galili D and Garfunkel AA: The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Dis 3(4): 243-246, 1997.
242. Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P, Corbi D, Puccio C, Chun H and Mittelman A: A Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 12(2): 131-132, 1993.
243. Oblon DJ, Paul SR, Oblon MB and Malik S: Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant 20(11): 961-963, 1997.
244. Prince HM, Regester G, Gates P, Jablonskis L, Seymour JF, Lillie K, West R, Wolf M, Januszewicz H and Belford D: A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patiens undergoing high-dose BEAM chemotherapy. Biol Blood Marrow Transplant 11(7): 512-520, 2005.
245. Rymes N, Glick L and Holmes JA: Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis Bone Marrow Transplant 18(2): 484, 1996.
246. Sprinzl GM, Galvan O, de Vries A, Ulmer H, Gunkel AR, Lukas P and Thumfart WF: Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 37(16): 2003-2009, 2001.
247. Prada A, Lozza L, Moglia D, Sala L and Chiesa F: Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity. Int J Tissue React 7(3): 237-239, 1985.
248. Prada A and Chiesa F: Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. Int J Tissue React 9(2): 115-119, 1987.
249. Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, Mailath G and Sinzinger H: Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg 28(2): 89-91, 1990.
250. Osaki T, Ueta E, Yoneda K Hirota J and Yamamoto T: Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants. Head Neck 16(4): 331-339, 1994.
251. Rosso M, Blasi G, Gherlone E and Rosso R: Effect of granulocyte- macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy. J Chemother 9(5): 382-385, 1997.
252. Mantovani G, Massa E, Astara G, Murgia V, Gramigano G, Lorusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C and Maccio A: Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Rep 10(1): 197-206, 2003.
253. Sprinzl GM, Galvan O, de Vries A, Ulmer H, Gunkel AR, Lukas P and Thumfart WF: Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 37(16): 2003-2009, 2001.
254. Tejedor M, Valerdi JJ, Arias F, Dominguez MA, Pruja E, Mendez L and Illarramendi JJ: Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma. Cytokines Cell Mol Ther 6(1): 35-39, 2000.
255. Abitbol AA, Sridhar KS, Lewin AA, Schwade JG, Raub W Jr, Wolfson A, Gonzalez-Angulo C, Adessa A, Goodwin WJ and Markoe AM: Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer 80(2): 266-276, 1997.
256. Hasenau C, Clasen BP and Roettger D: Use of standardized oral hygiene in the prevention and therapy of mucositis in patients treated with radiochemotherapy of head and neck neoplasms. Laryngol Rhinol Otol (Stuttg) 67(11): 576-579, 1988.
257. Samonis G, Rolston K, Karl C, Miller P and Bodey GP: Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 12 Suppl 3: S369-373, 1990.
258. Bodey GP, Samonis G and Rolston K: Prophylaxis of candidiasis in cancer patients. Semin Oncol 17(3 Suppl 6): 24-28, 1990.
259. Cerchietti LC, Navigante AH, Bonomi MR, Zaderajko MA, Menendez PR, Pogany CE and Roth BM: Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 95(10): 2230-2236, 2002.
260. Cerchietti LC, Navigante AH, Korte MW, Cohen AM, Quiroga PN, Villaamil EC, Bonomi MR and Roth BM: Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 105(1-2): 265-273, 2003.
261. Buntzel J, Kuttner K, Frohlich D and Glatzel M: Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol May 9(5): 505-509, 1998.
262. Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E and Feyerabend T: Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 179(6): 385-389, 2003.
263. Vacha P, Marx M, Engel A, Richter E and Feyerabend T: Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlenther Onkol 175 Suppl 4: 18-22, 1999.
264. Peters K, Mucke R, Hamann D, Ziegler PG and Fietkau R: Supportive use of amifostine in patients with head and neck turmors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine? Strahlenther Onkol 175 Suppl 4: 23-26, 1999
265. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M and de Vries A: Intravenous Amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64(3): 684-691, 2006.
266. Suntharalingam M, Jaboin J, Taylor R, Wolf Jm, Banglore M, Van Echo D and Ord R: The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy(RT). Semin Oncol 31(6 Suppl 18): 2-7, 2004.
267. Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K and Fleischer W: Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer 6(4): 373-377, 1998.
268. Naidu MU, Ramana GV, Ratnam SV, Sudhavani T, Naidu KJ, Roy P, Suresh P, Rani PU and Mohan IK: A randomized double-blind, parallel, placebo-controlled study to evaluate the efficacy of MF5232 (Mucotrol), a concentrated oral gel wafer, in the treatment of oral mucositis. Drugs R D 6(5): 291-298, 2005.
269. Lieschke GJ and Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 327(1): 28-35, 1992.
270. Bennett NT and Schultz GS: Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 165(6): 728-737, 1993.
271. Braunstein S, Kaplan G, Gottlieb AB, Schwartz M, Walsh G, Abalos RM, Fajardo TT, Guido LS and Krueger JG: GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo. J Invest Dermatol 103(4): 601-604, 1994.
272. da Costa RM, Aniceto C, Jesus FM and Mendes M: Quick healing of leg ulcers after molgramostim. Lancet 344(8920): 481-482, 1994.
273. Jyung RW, Wu L, Pierce GF and Mustoe TA: Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: differential action on incisional wound healing. Surgery 115(3): 325-334, 1994.
274. Masucci G: New clinical applications of granulocyte-macrophage colony-stimulating factor. Med Oncol Sep 13(3): 149-154, 1996.
275. Kaplan G, Walsh G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R et al: Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175(6): 1717-1728, 1992.
276. Raderer M, Kornek G, Hejna M, Koperna K, Scheithauer W and Base W: Topical granulocyte-macrophage colony-stimulating factor in patients with cancer and impaired wound healing. J Natl Cancer Inst 89(3): 263, 1997.
277. Zaghloul MS, Dorie MJ and Kallman RF: Interleukin 1 increases thymidine labeling index of normal tissues of mice but not the tumor. Int J Radiat Oncol Biol Phys 29(4): 805-811, 1994.
278. Zaghloul MS, Dorie MJ and Kallman RF: Interleukin-1 modulatory effect on the action of chemotherapeutic drugs and localized irradiation of the lip, duodenum, and tumor. Int J Radiat Oncol Biol Phys 26(3): 417-425, 1993.
279. Dorr W, Spekl K and Farrell CL: The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 35 Suppl 1: 86-92, 2002.
280. Farrell CL, Rex KL, Chen JN, Bready JV, DiPalma CR, Kaufman SA, Rattan A, Scully S and Lacey DL: The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 35 Suppl 1: 78-85, 2002.
281. Dorr W, Noack R, Spekl K and Farrell CL: Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol 77(3): 341-347, 2001.
282. Potten CS, Booth D, Cragg NJ, Tudor GL, O'Shea JA, Booth C, Meineke FA, Barthel D and Loeffler M: Cell kinetic studies in the murine ventral tongue epithelium: mucositis induced by radiation and its protection by pretreatment with keratinocyte growth factor (KGF). Cell Prolif 35 Suppl 1: 32-47, 2002.
283. Dorr W, Spekl K and Farrell CL: Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 54(1): 245-251, 2002.
284. Dorr W, Bassler S, Reichel S and Spekl K: Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental study in mice. Int J Radiat Oncol Biol Phys 62(3): 881-887, 2005.
285. Sonis ST, Costa JW Jr, Evitts SM, Lindquist LE and Nicolson M: Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 74(6): 749-755, 1992.
286. Dumbrigue HB, Sandow PL, Nguyen KH and Humphreys-Beher MG: Salivary epidermal growth factor levels decrease in patients receiving radiation therapy to the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89(6): 710-716, 2000.
287. Epstein JB, Gorsky M, Guglietta A, Le N and Sonis ST: The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89(11): 2258-2265, 2000.
288. Skubitz KM and Anderson PM: Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med 127(2): 223-228, 1996.
289. Carneiro-Filho BA, Oria RB, Wood Rea K, Brito GA, Fujii J, Obrig T, Lima AA and Guerrant RL: Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice. Nutrition 20(10): 934-941, 2004.
290. Curi R, Newsholme P, Pithon-Curi TC, Pires-de-Melo M, Garcia C, Homem-de-Bittencourt Junior PI and Guimaraes AR: Metabolic fate of glutamine in lymphocytes, macrophages and neutrophils. Braz J Med Biol Res 32(1): 15-21, 1999.
291. Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R, Morrow FD, Jacobs DO, Smith RJ, Antin JH et al: Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 116(10): 821-828, 1992.
292. Ziegler TR, Bye RL, Persinger RL, Young LS, Antin JH and Wilmore DW: Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation: a pilot study. Am J Med Sci 315(1): 4-10, 1998.
293. Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M, Rutella S, Cicconi S, Fiorini A, D'Onofrio G, Leone G and Sica S: Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 88(2): 192-200, 2003.
294. Cassati DR, Fazenbaker CA, Bachy CM and Hanson MS: Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol 12(1 Suppl 1): 97-102, 2002.
295. Bourhis J and Rosine D: Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Semin Oncol 29(6 Suppl 19): 61-62, 2002.
296. Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijdervet FK, Uges DR and Hospers GA: Outcomoe of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Res 24(5B): 3263-3267, 2004.
297. Andreassen CN, Grau C and Lindegaard JC: Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 13(1): 62-72, 2003.
298. High KP, Legault C, Sinclair JA, Cruz J, Hill K and Hurd DD: Low plasma concentrations of retinol and alpha-tocopherol in hematopoietic stem cell transplant recipients: the effect of mucositis and the risk of infection. Am J Clin Nutr 76(6): 1358-1366, 2002.